Introduction
============

Inflammatory lesions are associated to the most prevalent and morbid pathologies in developed countries including atherosclerosis [@B1], [@B2]{Libby, 2013 \#8681}, neurodegeneration [@B3], [@B4] diabetes or obesity [@B5], [@B6] and cancer [@B7]-[@B9], among others. Decreases in the inflammatory phenotype are known to reduce disease progression and improve patient´s quality of life, as well as to enhance recovery [@B7], [@B9]. With this aim, a variety of anti-inflammatory drugs have been proposed as adjuvant therapies for the different diseases, including mainly steroidal or non-steroidal treatments [@B10]-[@B12]. However, anti-inflammatory therapies demand the use of relatively large doses of the free drugs and inevitably end up developing, a collection of adverse secondary effects that preclude continuation of the treatment [@B13], [@B14]. On these grounds, methods to improve the efficiency of anti-inflammatory drug delivery to the lesion, decreasing the dose and increasing its selectivity and efficacy, entail considerable importance in a wide spectrum of diseases.

Liposomes have been proposed previously as novel nanotechnology formulations to improve drug delivery to a variety of inflammatory diseases [@B15]-[@B17]. Targeting of the inflammatory region may be achieved using, either active or passive approaches. Active targeting involves the use vectorial reagents embedded in the liposomal membrane that recognize epitopes of the target lesion [@B18]. Passive targeting refers to the passive accumulation of the liposomes in the inflamed regions because of the Enhanced Permeability Retention (EPR), an effect derived from their relatively increased capillary permeability and limited clearance [@B19]. In both targeting strategies, it becomes difficult to visualize non-invasively if the liposomal preparation has arrived to the target tissue and many times, only indirect measurements of the inflammation size or volume provide an index of the anti-inflammatory effect. It would become then very useful, to be able to locate directly and non-invasively the presence of the drug loaded liposomes in the lesion. Liposomes are optimal structures for this purpose, since they can be prepared to contain in their lumen, in addition to the anti-inflammatory drug, a variety of imaging probes including radioactive, fluorescent or superparamagnetic agents, among others [@B20]-[@B22]. The liposomal lumen can be loaded with water-soluble drugs, maintained in solution in the lumen, or lipid-soluble drugs, thought to incorporate spontaneously in the bilayer membrane [@B23], [@B24]. This approach is known as image guided drug delivery, representing currently a powerful strategy to diagnose and treat inflammatory diseases [@B25]-[@B28].

Important anti-inflammatory effects have been reported using preparations of omega-3 fatty acids [@B29]-[@B35], a kind of long chain polyunsaturated fatty acids (PUFAs) mainly present in fish oils and used as dietary supplement. Omega-3 PUFAs allow prolonged anti-inflammatory treatments without the appearance of the deleterious secondary effects of alternative steroidal or non-steroidal drugs [@B14], [@B36], operating simultaneously on a variety of targets of the inflammatory cascade.

In this work we report on a successful protocol to encapsulate ω-3 PUFA [@B37] containing in addition, either or both, the novel Nanotex superparamagnetic nanoparticle [@B38] or the Rhodamine-100 dye, thus allowing in vivo monitorization using magnetic resonance imaging or fluorescence. These advanced theranostic preparations maintain completely the therapeutic potential of free ω-3 PUFA, potentiated additionally with highly versatile multimodal imaging capabilities. We demonstrate here the anti-inflammatory effects of these preparations *in vivo*, in animal models of colonic and oncologic inflammation.

Materials and Methods
=====================

Preparation of Nanotex
----------------------

Nanotex is a superparamagnetic nanoparticle containing a magnetite (Fe~3~O~4~) core with poly(acrylic) acid coating. Magnetite (Fe3O4) nanoparticles were prepared by the co-precipitation of Fe^3+^ and Fe^2+^ ions (molar ratio 2:1) at 25 °C and a concentration of 0.3 M iron ions with ammonia solution (29.6%) at pH 10 in an inert atmosphere, followed by hydrothermal treatment at 80 °C for 30 min. For the binding of poly(acrylic acid) (PAA), 100 mg of Fe3O4 nanoparticles were first mixed with 2 mL of buffer *A* (0.003 M phosphate, pH 6) and 0.5 mL of carbodiimide solution (0.025 g/mL in buffer *A*). After being sonicated for 10 min, 2.5 mL of PAA solution (60 mg/mL in buffer *A*) was added and the reaction mixture was sonicated for another 30 min. Finally, the PAA-coated Fe3O4 nanoparticles were recovered magnetically, washed with water twice and dialyzed against a buffer saline solution. Nanotex preparations were highly water soluble, stable for several months, and depicted uniform diameters smaller than 15 nm [@B38].

Preparation and characterization of liposomes
---------------------------------------------

### Lipid film hydration and extrusion method

Liposomes were prepared essentially using the film hydration method [@B17], [@B39], [@B40]. Briefly, 20 mg (26 μmol) of L-α-phosphatidylcholine (PtdCho, Avanti Polar Lipids Inc. 840051P, Alabaster, Alabama, USA) were dissolved in 2 mL of chloroform (Merck, Darmstad, DE K36897545). The solution was placed in a round bottom flask and subjected to rotary evaporation (Heindolph Instruments, Schwabach, DE) for sixty minutes (280 rpm, 474 mBar, 40 °C). The lipid film formed after chloroform evaporation was further rotated under the same conditions to remove chloroform traces. Then, the dried lecithin film was rehydrated with 5 mL of water (containing or not the active principle and imaging probes) and rotated 60 minutes at atmospheric pressure and 50 °C. This process generates a heterogeneous suspension of liposomes of different sizes containing or not the active principles and imaging probes in their lumen or outside as delivered with the hydration buffer. To homogenize the size distribution, the liposomal suspension was extruded eleven times (Northen Lipids, Burnaby, CA) under nitrogen pressure through a 200 nm membrane (Whatman, GE Healthcare, Fairfield, Connecticut, US) maintaining the extrusor temperature at 50 °C. The resulting suspension containing homogenous liposomes, loaded or not with the selected imaging agent and ω-3 PUFA ethyl esther (ω-3 PUFA-EE), was stored at 4 °C until further utilization. Figure [1](#F1){ref-type="fig"}A provides a schematic description of the process.

We prepared liposomes encapsulating either suspensions of (i) buffer alone, (ii) Nanotex superparamagnetic nanoparticle (0.5 mg Fe/mL, Solutex S.L., Alcobendas, ES) as MRI detectable probe, (iii) Nanotex and ω-3 PUFA-EE (0.1% v/v final volume, 0.75 mM, 95% w/v eicosapentanoic acid ethyl ester, Solutex S.L., Alcobendas, ES) as theranostic anti-inflammatory agents detectable by MRI, or (iv) Nanotex with Rhodamine-100 chloride (10 mg/mL Sigma Aldrich, Barcelona, ES) as a novel hybrid imaging agent detectable by MRI and fluorescence.

### Centrifugal Ultrafiltration

The ultrafiltration method separates the crude liposomal preparation in two fractions, the sediment containing the liposomes, and the ultrafiltrate containing mainly the extraliposomal medium. This is achieved by forcing the crude liposomal preparation to pass through a filter of controlled pore size, under centrifugal acceleration. For this purpose, we used molecular size filters with a pass of 300 KDa (Vivaspin 6, MWCO 300 KDa, Vivaproducts, Littleton, MA, US). The centrifuge used was J-6B (Beckman Coulter, L\'Hospitalet de Llobregat, ES) with centrifugation conditions of 2891 G (3900 rpm, 20 °C, 1 hour). After the centrifugation, the absorption spectra (200 - 600 nm) of the sediment and the ultrafiltrate was obtained to determine the presence of PUFA- EE goticules using multiwall plates in a vertical spectrofluorometer (Synergy, Biotek, Winooski, VT, US).

### Size exclusion chromatography

Size exclusion chromatography separates the components of a heterogeneous sample according to their size or molecular weight. Those components larger than the pores of the matrix (Sephadex G-50, Sigma-Aldrich, Alcobendas, ES) are excluded from the exchange and proceed faster to the chromatographic front, while those components with smaller size than the matrix pore are temporally retained, with longer elution times for the smaller molecules [@B39].

The column dimensions were 1.8 x13 cm. Two grams of Sephadex G50 (swell capacity 1 g/9 mL) were hydrated with 40 mL of H~2~O Milli-Q (4 °C, 16 hours). After Sephadex hydration, the column was charged and compressed with H~2~O Milli-Q (250 mL), stabilizing the flux to 0.3 mL/min. Then, the Sephadex column was presaturated with an empty liposomes preparation to minimize non selective adsorption. Then, 300 μL of the crude liposomal preparation were added to column head and run (0.3 mL/min) with 50 mL of H~2~O Milli-Q. Fractions of the eluate were collected automatically (400 μL/90 sec, Biorad 210, BioRad Laboratories, Madrid, ES) and analyzed spectrophotometrically on a vertical plate reader (Synergy, BioTek, VT, US).

Figure [1](#F1){ref-type="fig"}B shows a representative elution profile from the gel filtration chromatography of a crude preparation of liposomes containing Nanotex and ω-3 PUFA-EE as monitored by measurements of absorbance (turbidity) at 380 nm. The first peak observed (peak 1), co-eluting with the solvent front, corresponds to large aggregates of extraliposomal Nanotex, since it is observed also when running liposome-free Nanotex preparations. The second peak (peak 2) corresponds to liposomes loaded with ω-3 PUFA-EE and Nanotex. Finally, the two peaks eluting later, correspond to small extraliposomal free individual Nanotex particles (peak 3) and external goticules of ω-3 PUFA-EE (peak 4) not entrapped within the liposome, since both co-elute with the corresponding standards, respectively. The comparison of the absorbance (turbidity) measurements between the crude preparation and the purified liposomal fractions lead us to the conclusion that liposomes encapsulate approximately 30% of the added ω-3 PUFA-EE or close to 100% of the added Nanotex.

### Dynamic Light Scattering

The size of liposomes (Figure [1](#F1){ref-type="fig"}C, [1](#F1){ref-type="fig"}D) was measured by Dynamic Light Scattering (DLS, DynaPro MS/X Wyatt Inc., Dernbach, DE) essentially as described by Berne et al. and Hallett et al. [@B41], [@B42]. A dilution 1:10 of the original samples in water was placed in a quartz cuvette inside the apparatus to perform the light scattering measurement.

### ^1^H High Resolution Magic Angle Spinning (HRMAS)

^1^H HRMAS spectroscopy was performed using a Bruker Avance 11.7 T instrument equipped with a High Resolution Magic Angle Spinning (HRMAS) accessory, interfaced with a Linux driven Paravision IV console (Bruker BIOSPIN, Ettlingen, DE). Briefly, samples were dissolved in deuterated water (25 μL, 99.2% ^2^H, Apollo Scientific Limited, Stockport, UK) or deuterated chloroform (25 μL, 99.8% ^2^H, Scharlau, Barcelona, ES) containing 1 mM TMS (tetramethyl silane, Scharlau, Barcelona, ES) or 1 mM TSP (trimetil sylil 2, 2\', 3, 3\' tetradeutero sodium propionate) as chemical shift references (0 ppm), respectively. Samples were placed in 50 µL zirconium rotors, inserted in the HRMAS probe and allowed 10 min for temperature equilibration. Water suppressed ^1^H HRMAS spectra (4 °C, 4000 Hz) were acquired using the Carr-Purcell-Meiboom-Gil sequence with π/2 pulses, spectral width 10 kHz, acquisition time 0.41 sec, D1=1 sec, and 72 π pulses equally separated τ=1 ms. Spectral processing used 1 Hz exponential line broadening function applied in the time domain data prior to Fourier Transformation [@B43].

2D COSY spectra were acquired using the sequence π/2-TD-π/2-acquire, with 2048 TD increments in the f~1~dimension and an acquisition time of 0,21s in the f~2~ dimension. Cross-Peak correlations were analyzed in contour plots obtained after two dimensional Fourier transformations.

^1^H NMR DOSY (Diffusion-Ordered NMR Spectroscopy) spectra of liposomal suspensions were acquired in a 400 MHz Bruker AVANCE III spectrometer (Bruker BIOSPIN, Ettlingen, DE) using a ^1^H selective probe and 5 mm NMR tubes. The spin-echo Stejskal-Tanner sequence, π/2-Δ-π-Δ-acquire, was used with Δ values of 20, 50 and 100 ms and sixteen linear increments of the diffusion weighting gradient ranging from 2% to 95% of the maximal gradient strength. [@B43].

### Water Relaxivity

We investigated the effect of magnetoliposomes on the T~1~ and T~2~ magnetic relaxation times of the water molecules of the suspension, to assess their potential usefulness as imaging agents for MRI detection. T~1~ and T~2~ relaxation times of magnetoliposomes were investigated in two different liposomal samples, containing or not the superparamagnetic particle Nanotex (0.5 mg Fe/mL). Dilutions of the original suspensions to 50% (v/v) and 25% (v/v) of the initial concentration were used to generate the relaxation vs. concentration profiles. r~1,2~relaxivity are the relaxation rates (1/T~1,2~) of the water protons and can be calculated by linear regression fittings of the r~1,2~values to the Fe concentration using the expression
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where r~1,2~represent the relaxivity in r~1~ or r~2~ (s^-1^·mmol^-1^); r0~1,2~, represents the relaxation rate of the water protons in the absence of magnetoliposomes, r1~1,2~the relaxation rate of the water protons in the presence of different concentrations of magnetoliposomes, and \[Fe\] the mM concentration of Fe in the magnetoliposomal suspension. Briefly, T~1~ or T~2~ values of all samples (37 °C) were measured using the inversion recovery sequence or Carr-Purcell-Meiboom-Gill (CPMG) sequences using a Bruker Minispec 1.5 Tesla time domain spectrometer (Bruker BIOSPIN, Ettlingen, DE) [@B44].

### Fluorescence

We investigated the fluorescent properties of magnetoliposomes labeled with Rhodamine-100 chloride both *in vitro* and *in vivo* using an *in vivo* IVIS-Lumina system (Perkin Elmer, Waltham, Massachusetts, USA) [@B45]. *In vitro* and *in vivo* fluorescence images were acquired using a Green Fluorescent Protein filter (GFP, 445-490 nm excitations, 515-575 nm emission) during sixty seconds of exposure time. For the *in vitro* studies, three samples of liposomes containing or not the nanoparticle (25 mg Fe/mL) and the fluorescent dye (10 mg/mL), at different concentrations (18.75 mg Fe/mL, 12.5 mg Fe/mL, 6.25 mg Fe/mL for the nanoparticle and 7.5 mg/mL, 5 mg/mL, 2.5 mg/mL for Rhodamine-100 were placed in 96-well plate and scanned. For the *in vivo* studies, CD1 adult mice (30 g body weight) were anesthetized in a ventilated chamber with a mixture of oxygen and isofluorane (2%, Isoflo, Esteve, Barcelona, ES) and maintained on it during the scanning period. Images were acquired as indicated above, five minutes before and three minutes after the i.p. injection (200 μL) of the liposomal preparations.

*In vivo* evaluation of anti-inflammatory activity
--------------------------------------------------

### Animal Models of Inflammation and experimental design

All animal procedures were approved by the corresponding institutional ethical committee (INCSIC) and were performed in accordance with Spanish (law 32/2007) and European regulations (EU directive 86/609, EU decree 2001-486). Mice were housed in cages containing three or four animals per cage, under controlled temperature (23 °C) and humidity (47%) conditions and twelve hours light/dark cycles (8h, lights on).

A convenient model of colonic inflammation was induced in adult male C56BL6 mice (30 g body weight, Charles River, L´Arbresle, FR) through the administration of Dextran Sulfate sodium salt (DSS, Leti, Barcelona, ES) in the drinking water (3.5% w/v) during 5 days [@B46]. Briefly, two groups of mice received DSS treatment for five days and were injected in the tail vein (100 µL) with Phosphate Buffered Saline (n=6, Group 1), or Magnetoliposomes containing ω-3 PUFA-EE (n=6, Group 2) once during the first three days. The evolution of the body weight was followed daily in each mouse until the fifth day when the animals were investigated by MRI. For this purpose, mice were injected i.p. with 100 µL of Gd(III)DTPA (0.1 M) just before coronal T~1w~ images were acquired from the rectal zone of each mouse. Colonic inflammation was measured by the thickness of the rectal wall. After the MRI experiment, the administration of DSS was stopped and normal drinking water was administered to all mice, following their recovery in body weight until day 10^th^ after DSS treatment initiation.

The model of oncologic inflammation was induced in CD1 mice (Charles River, L´Arbresle, FR) through the stereotaxic implantation of approximately 10^6^ C6 glioma cells in the caudate nucleus of the mouse brain [@B47]. Fifteen days after the implantation, the tumor had proliferated reaching diameters in the range 5-15 mm. Five different treatments were applied intravenously on day 15^th^ after implantation: Group 3 (n=4) received saline administrations only, Group 4 (n= 4) received a preparation of empty liposomes, Group 5, (n=4) received preparations of Magnetoliposomes without ω-3 PUFA-EE (100 μL) and Group 6 (n=4) preparations of Magnetoliposomes with PUFA-EE (100 μL), respectively. The growth of the glioblastoma after treatment was followed non-invasively in the same mouse on the day of treatment initiation (Day 0) and three (Day 3) or six days (Day 6) after by T~1w~ (Gd(III) enhanced) and T~2w~ MRI.

We considered using administrations of free ω-3 PUFA-EE as controls for the liposomal administrations in both models. However, the need to formulate stable aqueous emulsions of ω-3 PUFA-EE micelles for intravenous administration, and the different physico-chemical and pharmacokinetic properties between micelles and liposomes limited the selection of free ω-3 PUFA-EE as control, favoring its liposomal formulation.

### Magnetic Resonance Imaging

All MRI examinations were performed using a 7 Tesla horizontal magnet (16 cm bore) interfaced with a Bruker AVANCE III radiofrequency console operated through a Linux platform running Paravision V software (Bruker Biospin, Ettlingen, DE).

The colon inflammation model was explored with T~1~ images using a Multi Slice Multi Echo (MSME) sequence, TE=10.643 ms, TR=521 ms, 3 averages, axial orientation, 22 slices, slice thickness 1.5 mm, interslice distance 1.5 mm, field of view 3.8 cm.

The glioma model was investigated with T~1~and T~2~ weighted images. T~2~ images were acquired using a Rapid Acquisition with Relaxation Enhancement (RARE) sequence, TE=14.77 ms, TR=2500 ms, 6 averages, axial direction, 14 slices, slice thickness 1 mm, interslice distance 1 mm, field of view 2.3 cm. T~1~ images were acquired essentially using the similar conditions as for colonic inflammation with TR=350 ms, 14 slices, slice thickness 1 mm, interslice distance 1 mm, field of view 2.3 cm.

T~1~ images were always obtained after the i.p. administration of 100 μL of Gd(III)DTPA (0.1 M, Magnevist, Bayer Schering, Berlin, DE).

Statistical Analysis
--------------------

Comparisons used the mean and standard deviation of all data from each group and the t-student test to assess significance (p\<0.05). Statistical analysis was done using SPSS software (IBM, New York, NY, US).

Results
=======

Properties of the liposomal preparations
----------------------------------------

### Dynamic Light Scattering

The protocol for liposomal preparation originates a suspension of liposomes with homogenous size determined by the extrusion pore of the membrane. We determined experimentally the liposomal size by Dynamic Light Scattering (DLS). Figures [1](#F1){ref-type="fig"}C and [1](#F1){ref-type="fig"}D show representative results of size measurements by DLS in liposomal preparations without, or with, ω-3 PUFA-EE, respectively. DLS analysis of liposomes without ω-3 PUFA-EE showed 200 nm diameter vesicles only, corresponding well with the 200 nm filter used in the extrusion process. The liposomal preparations containing ω-3 PUFA-EE showed, in addition to the expected 200 nm liposomal particles, larger particles of approximately 7000 nm. These microparticles accumulated with time at the top of the suspension as a lipid layer and could be easily removed from the preparation before further use. Smaller size goticules of approximately 20-30 nm could also be detected by DLS.

### Magnetic Resonance Spectroscopy

To elucidate the nature of the incorporation of ω-3 PUFA-EE into the liposomal suspensions we implemented a study using High Resolution Magic Angle Spinning ^1^H Magnetic Resonance Spectroscopy (HRMAS).

Figure [2](#F2){ref-type="fig"} shows representative ^1^H HRMAS spectra from aqueous (Figure [2](#F2){ref-type="fig"}A, [2](#F2){ref-type="fig"}C) or chloroform (Figure [2](#F2){ref-type="fig"}B, [2](#F2){ref-type="fig"}D) suspensions of empty liposomes (left panels) and liposomes loaded with ω-3 PUFA-EE (right panels). The spectra of the chloroform suspensions show clearly resolved resonances from the magnetically different protons of L-α-phosphatidylcholine (PtdCho) and eicosapentaenoic acid (EPA, see Scheme [1](#SC1){ref-type="fig"} for the corresponding chemical structures). Complete assignments were achieved using literature values and confirmed experimentally by 2D COSY spectroscopy (Table [1](#T1){ref-type="table"}) [@B48], [@B49]. The comparison of ^1^H HRMAS spectra from aqueous suspensions of empty liposomes and liposomes containing ω-3 PUFA- EE demonstrates important differences. In particular, the ^1^H HRMAS of empty liposome suspensions (Figure [2](#F2){ref-type="fig"}A) shows only small resonances from sufficiently mobile methyl (\#1, Table [1](#T1){ref-type="table"}) and methylene (\#2, Table [1](#T1){ref-type="table"}) protons of the sn~1~ and sn~2~ fatty acyl chains from L-α-phosphatidylcholine, most probably those located far away from the choline headgroup and closer to the center of the bilayer [@B50]. However, the motional restrictions of the bilayer arrangement impose the broadening and virtual disappearance of most phosphatidylcholine resonances, including particularly those of the choline headgroups (\#6, Table [1](#T1){ref-type="table"}) which are clearly observed in chloroform suspensions (Figure [2](#F2){ref-type="fig"}B, arrow) but not in aqueous suspension (Figure [2](#F2){ref-type="fig"}A, arrow). The insert in Figure [2](#F2){ref-type="fig"}A, illustrates the typical bilayer structure adopted by PtdCho molecules in liposomes with the choline headgroups oriented towards the external and internal aqueous interfaces. The insert in Figure [2](#F2){ref-type="fig"}B shows the PtdCho molecules in chloroform suspension adopting either the unimolecular or inverted micelle arrangements with the sn~1~ and sn~2~ chains oriented towards the solvent.

The incorporation of ω-3 PUFA-EE (red molecules) into liposomes originates important spectral changes. Notably, most resonances of ω-3 PUFA-EE observed in chloroform (Figure [2](#F2){ref-type="fig"}D) become now observable in the aqueous suspension (Figure [2](#F2){ref-type="fig"}C). This means that the dynamics of ω-3 PUFA-EE are similar in aqueous and chloroform suspensions, indicating that ω-3 PUFA-EE may be present as stable nanogoticules in both cases. These findings were confirmed by the DLS measurements (Figure [1](#F1){ref-type="fig"}D) which revealed clearly the presence of sufficiently small, fast tumbling, PUFA-EE nanogoticules of approximately 30 nm diameter (see red nanogoticule in the Insert Figure [2](#F2){ref-type="fig"}C).

However, nanogoticule formation may not be the only form of ω-3 PUFA-EE integration in the liposomes. Interestingly, note that resonance 20 in chloroform (Figure [2](#F2){ref-type="fig"}D), originated from the olefin protons (Table [1](#T1){ref-type="table"}), is approximately three times higher than resonance 19 corresponding to the α-methylene protons of the ester group. Notably, the relative intensity of resonance 20 as compared to resonance 19, decreases drastically in the aqueous suspension (Figure [2](#F2){ref-type="fig"}C), suggesting a significant degree of immobilization of the olefinic protons from ω-3 PUFA-EE under these conditions. This finding is indeed compatible with a partial integration of the ω-3 PUFA-EE in the liposomal bilayer, a process involving the formation of an α-helical structure stabilizing the chain of conjugated double bonds within the membrane, resulting in partial immobilization and ^1^H NMR invisibility [@B51], [@B52]. This is illustrated in the insert of Figure [2](#F2){ref-type="fig"}C by the red molecules of ω-3 PUFA-EE inserted in the bilayer membrane.

The above mentioned experiments do not clarify the intraluminal or extraliposomal localization of the nanogoticules. To investigate this aspect we performed Diffusion Weighted Spectroscopy experiments (DOSY, Figure [3](#F3){ref-type="fig"}) [@B53]. This approach measures the Apparent Diffusion Coefficient of water (ADC) in the liposomal preparation. According to the Einstein´s principle the ADC is inversely proportional to the number of molecular obstructions that the water molecule would find along its random mean diffusional path [@B54]. ADC measurements under these conditions are known to be dominated by the contribution of the extraliposomal volume and if goticules would be present there at a significant proportion, one would expect a decrease in the observed ADC. In contrast, if goticules would be located inside the liposomes, no additional obstructions would be found, because of the small contribution of the lumen space to total volume of the suspension, and consequently, very similar ADC´s would be measured in the presence and absence of ω-3 PUFA-EE. We found no significant differences in the water ADCs values between both preparations at the three diffusion times investigated, suggesting that the fatty acids ester nanodroplets do not increase significantly the molecular obstructions to water movements. Since the ADCs are primarily dominated by those of the extraliposomal volume, our results suggest that most PUFA-EE goticules are localized in the intraluminal space.

This could be directly demonstrated by the ultrafiltration experiments in which the goticules of ω-3 PUFA-EE model suspensions passed easily and quite completely the 300 kD filters, while the suspensions of liposomes containing ω-3 PUFA-EE did not passed through filters of identical dimensions, retaining most of the PUFA-EE goticules. This confirmed that ω-3 PUFA-EE goticules are predominantly intraluminal as indicated by the water ADC measurements.

Taking together these evidences allow for the conclusion that liposomal loading with ω-3 PUFA-EE, involves both, the formation of nanogoticules located in the liposomal lumen as well as the integration of ω-3 PUFA-EE within the liposomal bilayer.

### Magnetic relaxation properties

We investigated the T~1~ and T~2~magnetic relaxation properties of water molecules in suspensions of liposomes, containing or not Nanotex. Tables [2](#T2){ref-type="table"} and [3](#T3){ref-type="table"} summarize these results.

Table [2](#T2){ref-type="table"} shows the values of the T~1~ water relaxation time in liposome suspensions containing or not Nanotex in three successive dilutions of the initial concentration. The T~1~relaxation value is shortest for the highest Nanotex concentration, increasing approximately linearly when suspensions are further diluted, giving a relaxivity value r~1~ of 6.26 mM^-1^s^-1^. The same situation is observed with empty liposomes, albeit with a much smaller slope for the increase in T~1~ relaxation time due to the absence of the superparamagnetic nanoparticle.

Table [3](#T3){ref-type="table"} shows the results of T~2~ water relaxation measurements in the different samples. T~2~ values for the original sample with Nanotex depicted approximately one thousand times faster relaxation than the empty liposomes (Table [3](#T3){ref-type="table"}). The T~2~relaxation value is shortest for the highest Nanotex concentration and increases approximately linearly when the liposomal suspensions are diluted, giving a relaxivity value r~2~ of 64.6 mM^-1^s^-1^. The same situation is observed with empty liposomes, albeit with a much lower increase of T~2~ relaxation upon dilution and significantly smaller relaxivity. In summary, the relaxivity value r~1~ increases from 0.55 mM^-1^s^-1^ for free Nanotex [@B38] in suspension to 6.26 mM^-1^s^-1^ for Nanotex encapsulated in liposomes. In the case of r~2~, the value of 88.97 mM^-1^s^-1^ for free Nanotex [@B38] in solution decreases to 64.61 mM^-1^s^-1^ for encapsulated Nanotex.

### Fluorescence *in vitro* and *in vivo*

The capacity of liposomes as optical biomarkers was tested using *in vitro* and *in vivo* fluorescence. Figure [4](#F4){ref-type="fig"} summarizes the results obtained *in vitro* and *in vivo* with liposomes containing or not Nanotex, and labeled fluorescently with Rhodamine-100.

Figures [4](#F4){ref-type="fig"}A-B show results obtained in an *in vitro* fluorescence experiment, comparing in a multiwell plate, the fluorescence of empty liposomes (left track, white triangle), liposomes containing Rhodamine-100 (central track, green triangle) and liposome containing Rhodamine-100 and Nanotex (right track, blue triangle). Liposomes containing only Rhodamine-100 present more intense fluorescence than liposomes containing both Rhodamine-100 and Nanotex. This may be due to either or both of two circumstances. First, liposomes with Nanotex have to share their lumen space with Rhodamine-100 and one or more nanoparticles, resulting in a smaller intraluminal volume available for Rhodamine-100 accumulation and thus decreased intraluminal Rhodamine-100 concentration. Second, the Nanotex acrylic acid coating or its magnetite core could partially quench the fluorescence of Rhodamine-100.

Figure [4](#F4){ref-type="fig"}C shows the results of a representative *in vivo* experiment in a mouse receiving an i.p. injection of liposomes labeled with Rhodamine-100 containing (left) or not (right) Nanotex. As in the *in vitro* experiments, liposomes with Nanotex and Rhodamine-100 (left) depict less quantum efficiency than liposomes with only Rhodamine-100, however, they still become observable by *in vivo* fluorescence (Figure [4](#F4){ref-type="fig"}C).

Anti-inflammatory effects in vivo
---------------------------------

### Mouse model of colonic inflammation

We investigated the anti-inflammatory effects of liposomal preparations containing or not ω-3 PUFA-EE using a well-established model of colonic inflammation induced by dextran sulfate (sodium salt, DSS) administration [@B46], [@B55]. Untreated mice showed significant decreases in body weight, while mice treated with magnetoliposomes containing ω-3 PUFA-EE reduced appreciably the loss of body weight along the treatment period (not shown), revealing a potent anti-inflammatory effect of the formulation.

Figure [5](#F5){ref-type="fig"} shows representative results of the administration of saline (Figure [5](#F5){ref-type="fig"}A) or magnetoliposomes containing ω-3 PUFA-EE (Figure [5](#F5){ref-type="fig"}B) to mice with rectal inflammation induced by DSS. Saline treated mice showed, as expected, clearly increased colonic wall thickness, easily observable in T~1w~ images after Gd(III)DTPA enhancement. However, mice treated with magnetoliposomes containing ω-3 PUFA-EE (Figure [5](#F5){ref-type="fig"}B) depicted a significant reduction in colonic wall thickness, revealing a prominent anti-inflammatory effect of the theranostic formulation (Figure [5](#F5){ref-type="fig"}C-D). Notably, treatment with magnetoliposomes resulted, not only in a reduction of the rectal wall thickness, but in a significant darkening of this structure, a clear indication of the presence of magnetoliposomes in the inflamed region.

### C6 glioma mouse model

We then examined the effects of magnetoliposomes containing or not ω-3 PUFA-EE in the inflammation associated to glioma growth [@B8], using the C6 glioma models.

Figure [6](#F6){ref-type="fig"} shows representative MRI T~1w~ images of glioma evolution in a mouse treated with magnetoliposomes containing (bottom panels) or not (upper panels) ω-3 PUFA-EE. Mice receiving magnetoliposomes without ω-3 PUFA-EE developed tumors to the same extent than controls receiving saline (not shown). However, mice receiving magnetoliposomes containing ω-3 PUFA-EE decreased notably the rate of glioma growth, and even increased the regression rate of the implanted gliomas. Table [4](#T4){ref-type="table"} compares the effects of administering magnetoliposomes containing ω-3 PUFA-EE with control administrations of saline, empty liposomes or liposomes containing Nanotex only. The data show that the administration of magnetoliposomes containing ω-3 PUFA EE to mice bearing C6 tumors preserved the life of mice and induced a decrease in tumor size, while the administration of saline, empty liposomes or magnetoliposomes containing only Nanotex did not preclude death of the animals nor reduced tumor growth.

In addition to the MRI results, it becomes important to comment the external aspect and behavior of the mice. Mice with no treatment depicted bristly hair, decrease in motor activity and eventually hemiplegia and hemiparesis. Mice treated with liposomes with PUFA-EE did not present such symptoms, revealing significantly better physiopathological state and sometimes regression of the tumor.

Discussion
==========

We have presented a novel liposomal formulation combining the therapeutic properties of ω-3 PUFA-EE with the non-invasive multimodal imaging capabilities of Nanotex and Rhodamine-100, or the combination of both.

Interestingly, the encapsulation of a superparamagnetic nanoparticle in a liposome results in different relaxivity properties as compared to those of the free nanoparticle in suspension. These changes reflect necessarily modifications in the dynamics of the nanoparticle-water interaction induced by the encapsulation process. Indeed it would be expected that the encapsulation would decrease the interaction of the nanoparticle with the surrounding solvent water, because of the water impermeable liposomal membrane. These reduction effects are expected to occur mainly in the "outer sphere" relaxivity component, representing approximately 50% of the total relaxivity [@B56], [@B57]. The approximately 30% decrease observed in r~2~follows closely enough this interpretation. However, a similar decrease would also be expected to occur in r~1~. This is not observed, indicating that the "outer sphere" effect is not the only determinant of the changes in relaxivity occurring after liposomal encapsulation. The r~1~ value shows, in contrast, an important increase, larger than an order of magnitude. The most probable cause of this increase is the restriction in the rotational movement of the nanoparticle when present in the encapsulated lumen environment. This may be imposed by, either an association to the liposomal membrane, an increase in intraluminal microviscosity, or binding or interaction with neighboring nanoparticles, resulting in a slower tumbling time (τ~r~ in [@B57]). Indeed r~1~ and r~2~ have different determinants and behavior, as explained from their different Solomon-Bloembergen-Morgan equations [@B57]-[@B60], and it is not surprising that they respond differently to encapsulation. Moreover, r~1~ and r~2~, reflect the different time scales of T~1~ (s) and T~2~(ms), making easier to understand that the events occurring in the ms range of T~2~, may be too fast to be detected in the second range time-scale of T~1~. In summary, the encapsulation of Nanotex in liposomes appears to decrease the "outer sphere" contribution, reflecting water diffusional limitations imposed by the liposomal membrane, and a decrease in the tumbling time of the nanoparticle, revealing associations to the liposomal membrane or to other nanoparticles in the lumen. In this respect, our results are similar to those previously described in literature [@B61]-[@B63].

Present results on the encapsulation of ω-3 PUFA-EE in liposomes complement and extend previous studies [@B64]-[@B66]. Our results show that it is possible to encapsulate significant amounts of lipid soluble ω-3 PUFA-EE goticules in the liposomal lumen. This can be observed by the prominent ^1^H HRMAS resonances of liposomal suspensions containing the encapsulated fatty acids. The fact that these resonances are observed reveals that the ω-3 PUFA-EE are mainly present as small, fast tumbling nanogoticules in the liposomal lumen. This is because ω-3 PUFA-EE nanogoticules pass easily through 300 kD filters, while the encapsulated ω-3 PUFA-EE goticules, are retained by the same filters together with the liposomes. This finding is further confirmed by the fact that liposomal preparations containing encapsulated ω-3 PUFA-EE show the same ADC as the empty liposomal preparations, revealing that the obstructions caused by the presence of ω-3 PUFA-EE goticules do not contribute appreciably to the average ADC of the suspension, dominated by the extraliposomal compartment.

Our results provide also evidence that a significant portion of the encapsulated ω-3 PUFA-EE is inserted within the liposomal bilayer. This is because the ω-3 PUFA-EE molecules inserted in the membrane adopt an α-helical structure around the olefinic protons [@B51], becoming rotationally immobilized and ^1^H HRMAS undetectable [@B52]. This circumstance is easily observed in resonance 20 (Figure [2](#F2){ref-type="fig"}C-[2](#F2){ref-type="fig"}D), which shows full intensity in chloroform and roughly 30% intensity in water. This suggests that approximately 70% of encapsulated ω-3 PUFA-EE becomes inserted in the membrane and ^1^H HRMAS invisible, while 30% forms ^1^H HRMAS observable nanogoticules in the liposomal lumen.

The fluorescence study shows (Figure [4](#F4){ref-type="fig"}C) that the in vivo fluorescence signal from Rhodamine-100 contained in magnetoliposomes is weak, superimposes on significant endogenous fluorescence and fades away progressively when the liposomes distribute later over a larger volume, as in colonic inflammation models. Moreover, the presence of Nanotex quenches considerably the fluorescence of Rhodamine-100 (Figure [4](#F4){ref-type="fig"}B), making in vivo fluorescence detection not advisable for this agent under the present conditions. Furthermore, in vivo fluorescence applications to the brain are largely limited by the presence of the skull, an opaque bone structure hampering severely fluorescence detection. Taken together, the reduced fluorescence of our nanoparticles and the presence of the skull, dissuaded further fluorescence applications to the brain.

We show here also that the magnetoliposomal preparations containing Nanotex and ω-3 PUFA-EE present prominent anti-inflammatory activities against colonic inflammation and important antitumoral effects against glioma while becoming simultaneously observable in vivo by MRI.

Colonic inflammation is a disease associated to ulcerative colitis and Chron´s disease, two incurable pathologies at present. These are treated currently with conventional anti-inflammatory therapies, mainly free steroidal or immunosuppressant drugs, and eventually colonic resection by surgery [@B67]. The formulation proposed here has been shown to become therapeutically useful in animal models of DSS intoxication, adding a new, non-toxic formulation to the arsenal of therapeutic methods against these two morbid and prevalent diseases.

Finally, our liposomal formulation encapsulating ω-3 PUFA-EE and Nanotex has demonstrated valuable effects against glioma C6, slowing down proliferation and even inducing remission. These effects are due to the combination of Nanotex and the ω-3 PUFA-EE since they are not induced by empty liposomes or liposomes containing ω-3 PUFA-EE only. The precise mechanism of this unexpected cooperative effect remains to be elucidated, but could probably involve a significant decrease in the pro-inflammatory component required for glioma proliferation or invasion and iron modulation of reactive oxygen species [@B8], [@B9], [@B68].

In summary, present results illustrate the properties and use of a new nanotechnological formulation including one or more imaging agents and a therapeutic ω-3 PUFA-EE, useful in the treatment of the inflammatory component of colonic inflammation or glioma in animal models. A patent has been filed protecting the preparation, properties and use of this formulation [@B69].
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ADC

:   apparent diffusion coefficient

COSY

:   correlation spectroscopy

CPMG

:   Carr-Purcell-Meiboom-Gill

DLS

:   dynamic light scattering

DOSY

:   diffusion ordered NMR spectroscopy

DTPA

:   diethylendiamino pentaacetic acid

EPR

:   enhanced permeability retention

GFP

:   green fluorescent protein

HRMAS

:   high resolution magic angle spinning

i.p.

:   intraperitoneal

i.v.

:   intravenously

MRI

:   magnetic resonance imaging

MSME

:   multi slice multi echo

NMR

:   nuclear magnetic resonance

PAA

:   poly(acrylic acid)

PtdCho

:   L-α-phosphatidylcholine

PUFA-EE

:   polyunsaturated fatty acid ethyl ester

RARE

:   rapid acquisition with relaxation enhancement

T~1~

:   longitudinal relaxation time

T~2~

:   transversal relaxation time

T~1w~

:   image weighted in longitudinal relaxation time

T~2w~

:   image weighted in transversal relaxation time

TMS

:   tetramethyl silane

TSP

:   trimetil sylil-2, 2\', 3, 3\'tetradeutero- sodium propionate.
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![**Preparation and characterization of liposomes.** A:Liposomes are prepared from egg yolk lecithin, containing or not ω-3 PUFA-EE, Nanotex or Rhodamine-100 by the film hydration method [@B39]. A solution of chloroform and lecithin is rotated under vacuum to remove chloroform, depositing a thin lecithin film covering the round bottom flask. Hydration of this film with aqueous buffer results liposomes of heterogeneous sizes and different numbers of layers. Nanotex (black circles), ω-3 PUFA-EE (yellow circles) or Rhodamine-100 (red circles) may be added to the buffer, resulting in their intraluminal encapsulation. Some residual Nanotex, ω-3 PUFA-EE or Rhodamine-100 may remain in the extraliposomal space. Repeated extrusions (x11) result in crude homogeneous suspensions of liposomes loaded or not with added components in their lumen, but present also in the extraliposomal space. These may be removed later after a purification process, normally based in size exclusion chromatography (Sephadex G50) or centrifugal ultrafiltration through filters of controlled pore size. B: Absorption (turbidity) peaks at 380 nm from the column fractions loaded with a sample of liposomes with Nanotex and ω-3 PUFA-EE*.*Note that the elution profile presents an initial peak 1 corresponding to large Nanotex particle aggregates not encapsulated in the liposomes, followed by the most prominent peak 2 derived from liposomes containing PUFA-EE goticules and Nanotex, and extraliposomal free Nanotex particles (peak 3) or PUFA-EE goticules (peak 4). Representative *DL*S of a suspension of empty liposomes (C) and a suspension of liposomes loaded with ω-3 PUFA-EE (D). Black arrows indicate the size of smaller or larger aggregates of free ω-3 PUFA-EE.](thnov05p0489g001){#F1}

![**Characterization of liposomes loaded with ω-3 PUFA-EE by Magnetic Resonance Spectroscopy.**Representative HRMAS spectra (500.13 MHz, 4 °C, 4000 Hz rotation) of aqueous (A, C) and chloroform (B, D) suspensions from empty liposomes (A, B) and from liposomes loaded with ω-3 PUFA-EE (C, D). Resonance numbers refer to the assignments indicated in Table [1](#T1){ref-type="table"} and the structures depicted in Scheme [1](#SC1){ref-type="fig"}. Inserts A and B depicts schematically the organization of PtdCho molecules (blue) in the bilayer structure of aqueous liposomal suspensions or in the chloroform suspension as individual PtdCho molecules or inverted micelles with the choline headgroups oriented inwards. Inserts C or D illustrate the localization of ω-3 PUFA-EE inserted in the membrane or nanogoticules in the lumen of aqueous liposomal suspensions, or the inverted micelles and free molecules of PtdCho and ω-3 PUFA-EE in chloroform suspensions, respectively.](thnov05p0489g002){#F2}

![Chemical Structures of PtdCho (top, blue protons) and ω-3 PUFA-EE (bottom, red protons).](thnov05p0489g003){#SC1}

![**Characterization of PUFA-EE nanogoticule localization.**^1^H NMR DOSY (400,7 MHz, 22 °C) spectra of translational water diffusion in liposomal suspensions at different diffusion times Δ. Spectra were obtained from liposomal suspensions loaded (top panels) or not (bottom panels) with ω-3 PUFA-EE, with Δ of 100 ms (left), 50 ms (center) and 20 ms (right). Note that the presence of ω-3 PUFA-EE does not decrease significantly the water ADC at any of the diffusion times investigated, suggesting primarily an intraluminal location of the goticules.](thnov05p0489g004){#F3}

![**Fluorescence imaging of liposomes.** *In vitro* (A, B) and *in vivo* (C) fluorescence images of liposomes loaded with nanoparticles and Rhodamine-100 as acquired with an IVIS-Lumina camera. A: Visible picture of the 96 well plate used as phantom, showing the columns of wells loaded with decreasing concentrations (top to bottom) of empty liposomes (white triangle), liposomes loaded with Rhodamine-100 (green triangle) and liposomes loaded with Rhodamine-100 and Nanotex (blue triangle). B: Fluorescence image of the same phantom using the Green Fluorescent Protein (GFP) filter. Note the increased fluorescence of the liposomes containing Rhodamine-100 only as compared to those containing Rhodamine-100 and Nanotex. C: *In vivo* images of a mouse injected with liposomes containing Rhodamine-100 and Nanotex (left side arrow), or liposomes containing Rhodamine-100 only (right side arrow).](thnov05p0489g005){#F4}

![**Theranostic effects on colonic inflammation.**T~1w~ MRI of colonic inflammation in the rectal region of mice subjected to oral DSS administration for five days. A: untreated, B: treated with liposomes loaded with Nanotex and ω-3 PUFA-EE. Note the darker appearance of the rectum (arrows) from the mouse receiving magnetoliposomes loaded with Nanotex, revealing the presence of the nanoparticle. Wall thickness is illustrated by the orange line. Mean and standard deviation from measurements of rectal wall thickness (C) and wall area (D) are shown under the different conditions.](thnov05p0489g006){#F5}

![**Theranostic effects on tumoral inflammation and growth.** Effect of magnetoliposomal preparations containing (bottom) or not (top) ω-3 PUFA-EE on the time course of glioma development after implantation of C6 cells in the caudate nucleus of the mouse brain. T~2w~ images were acquired as indicated in methods. Left panels: (day 0), central panels (day 3), right panels (day 6). Note the accumulation of magnetoliposomes loaded with PUFA-EE revealed by the darkening of the tumoral lesion (arrow) and the eventual disappearance of the tumor six days after treatment. Table [4](#T4){ref-type="table"} summarizes the results obtained with animals surviving day 6.](thnov05p0489g007){#F6}

###### 

Assignments of phospholipid and ω-3 PUFA-EE ^1^H NMR resonances in water and chloroform suspensions.

                Resonance number               Assignment ^a)^   δ~HDO~^b)^       δ~CDCl3~^c)^
  ------------- ------------------------------ ----------------- ---------------- ---------------
  Liposomes     1                              H~16,~H~53~       0.9              0.89-0.86 (m)
  2             H~17-28~, H~38-41~, H~47-52~   1.32              1.25 (m)         
  3             H~29~, H~37~                   n.o. ^d)^         1.57 (m)         
  4             H~42-46~                       n.o. ^d)^         2.02 (m)         
  5             H~30~, H~36~                   n.o. ^d)^         2.34-2.26 (dt)   
  6             H~8~, H~10~, H~11~             n.o. ^d)^         3.28 (t)         
  7             H~6~                           n.o. ^d)^         3.77 (t)         
  W             Water                          4.79              \-               
  8             H~12~                          n.o. ^d)^         4.05 (m)         
  9             H~14~                          n.o. ^d)^         4.13 (m)         
  10            H~5~                           n.o. ^d)^         4.37 (m)         
  11            H~15~                          n.o. ^d)^         5.23 (m)         
  12            H~43~, H~45~                   n.o. ^d)^         5.33 (m)         
  ω-3 PUFA-EE   13                             H~23~             1.03             0.97 (t)
  14            H~1~                           1.27              1.25 (t)         
  15            H~6~                           1.73              1.7 (q)          
  16            H~7~, H~22~                    2.19-2.14         2.32-2.07 (m)    
  17            H~5~                           2.32              2.3 (t)          
  18            H~10~, H~13~, H~16~, H~19~     2.9-2.87          2.85-2.8 (m)     
  19            H~2~                           4.12              4.12 (t)         
  W             Water                          4.79              \-               
  20            H~25-34~                       5.46-5.40         5.38-5.30 (m)    

^a)^ Resonances 1-20 in Figure [2](#F2){ref-type="fig"} are assigned to specific protons of the corresponding PtdCho and ω-3 PUFA-EE molecules (see Scheme [1](#SC1){ref-type="fig"} for proton numbering).

^b)^ Chemical shifts are measured in ppm and referenced to TSP at 0 ppm.

^c)^ Chemical shifts are measured in ppm and referenced to TMS at 0 ppm.

^d)^ The resonances marked with "n.o." are not observable by high resolution ^1^H HRMAS because of dynamical restrictions in the bilayer.

###### 

T~1~ values of aqueous liposomal suspensions containing or not Nanotex in decreasing concentrations.

  Suspension type /dilution ^a)^   T~1~ (ms) ^b)^                    
  -------------------------------- ---------------- ---------------- --------------
  Liposomes w/ nanoparticles       17.3 ± 0.0       34.2 ± 0.1       64.1 ± 0.1
  Liposomes w/o nanoparticles      2161.7 ± 154.6   2207.3 ± 107.9   2955.0 ± 7.1

^a)^ The dilutions (v/v) of the liposomal preparations correspond to the original liposomal suspension (5.26 mM PtdCho, x1), 50% (x1/2) or 25% (x1/4). In the liposomal preparations containing Nanotex these dilutions correspond to iron concentrations of 0.5 mg Fe/mL, 0.25 mg Fe/mL and 0.125 mg Fe/mL.

^b)^T~1~ values were determined at 1.5 Tesla (22 °C, Bruker Minispec, Rheinstetten, DE) using the inversion recovery sequence.

###### 

T~2~ values of aqueous liposomal suspensions containing or not Nanotex in decreasing concentrations.

  Suspension type /dilution ^a)^   T~2~(ms) ^b)^                  
  -------------------------------- --------------- -------------- --------------
  Liposomes w/ nanoparticles       1.7 ± 0.0       3.5 ± 0.0      6.6 ± 0.0
  Liposomes w/o nanoparticles      1138.3 ± 34.6   1034.3 ± 6.1   2228.2 ± 0.1

^a)^ The dilutions (v/v) of the liposomal preparations correspond to the original liposomal suspension (5.26 mM PtdCho, x1), 50% (x1/2) or 25% (x1/4). In the liposomal preparations containing Nanotex these dilutions correspond to iron concentrations of 0.5 mg Fe/mL, 0.25 mg Fe/mL and 0.125 mg Fe/mL.

^b)^T~2~ values were determined at 1.5 Tesla (22 °C, Bruker Minispec, Rheinstetten, DE) using the inversion recovery sequence.

###### 

Assesment of C6 tumor growth in mice receiving magnetoliposomes containing or not ω-3 PUFA-EE.

  Type of liposomal preparation injected ^a)^   Mouse ^b)^   Initial size (mm^2^) ^c)^   Final size (mm^2^) ^d)^   \% increase or decrease tumor size after treatment
  --------------------------------------------- ------------ --------------------------- ------------------------- ----------------------------------------------------
  None, saline                                  Mouse 1      12.72                       18.87                     +48.35%
  Mouse 2                                       38.89        131.82                      +238.96%                  
  Empty Liposomes                               Mouse 5      13.46                       26.92                     +200,00%
  Mouse 6                                       18.37        76.23                       +414,90%                  
  Nanotex Liposomes                             Mouse 9      15.756                      27.5                      +74.54%
  Mouse 10                                      14.473       20.212                      +39.65%                   
  Mouse 11                                      8.298        13.787                      +66.15%                   
  Nanotex + ω-3 PUFA-EE Liposomes               Mouse 13     12.624                      2.825                     -77.62%
  Mouse 14                                      6.07         0.396                       -93.48%                   
  Mouse 15                                      8.952        0.347                       -96.12%                   
  Mouse 16                                      24.377       10.179                      -58.24%                   

^a)^Liposomal preparations were administered i.v. through the tail vein fifteen days after C6 cell implantation.

^b)^ Groups containing four mice at the time of treatment initiation were used in all conditions. Only the mice surviving six days after treatment initiation are shown.

^c)^ Tumor size before treatment initiation.

^d)^ Tumor size after six days of treatment.

^c,d)^ Tumor area (mm^2^) reflects the area including the tumor and peripheral inflammation as detected in coronal cross sections of T~2w~ images obtained before (initial) or six days after (final) treatment.
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